国际多中心对象研究,对Beta-Blocker-Free治疗策略的Beta-Blocker-Free治疗策略,对于Catecholaminergic多态风性心动节拍患者
Raquel Neves1, Sahej Bains2, J Martijn Bos3
1Department of Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo Clinic, Rochester, Minnesota, USA.
JACC. Clinical electrophysiology
|December 21, 2024
概括
对于患有白内障多形心室性心动减速症 (CPVT) 的患者,经历β-阻断剂 (BB) 的副作用,存在安全有效的无BB的策略. 仔细的风险评估允许在10%的CPVT患者中量身定制的BB-free治疗配置.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- catecholaminergic多形心室性心力衰竭 (CPVT) 是一种罕见的,危及生命的遗传性心脏病.
- 非选择性β抑制剂 (BBs) 是管理CPVT的标准,但有些患者会出现不良反应.
- 对于不耐受BBs的患者,需要采用替代治疗策略.
研究的目的:
- 审查在CPVT患者中没有BB的治疗选择和结果.
- 分析来自国际CPVT注册表的BB-free策略数据.
- 为 CPVT 管理确定有效的 BB-free 配置.
主要方法:
- 从国际CPVT注册表中包括RYR2变异阳性CPVT患者,接受BB无治疗6个月以上.
- 分类为两组:非常低风险患者的故意非治疗 (INT) 和BB不耐受患者的替代策略.
- 对治疗策略的分析,包括弗莱卡尼德单一治疗和左心交感性缩.
主要成果:
- 在1017名CPVT患者 (100人) 中,有10%使用了无BB的策略.
- 73名患者在INT组中,主要是无症状的低风险个体.
- 27名患者接受了替代的BB-free策略 (flecainide,交感性消神或两者兼而有之),在6年的中位随访期间仅发生了2起事件.
结论:
- 虽然BBs是CPVT的主要治疗方法,但10%的患者需要BB-free方法.
- 经过仔细的风险分层,可以制定安全有效的无BB治疗计划.
- 没有BB的策略为选择的CPVT患者提供了可行的替代方案.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
Heart Failure Drugs: β-Blockers
315
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
520
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
520
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
528
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
528
Adrenergic Antagonists: ɑ and β-Receptor Blockers
405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405
Increased pulse rate
637
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
637


